GET DAILY SIGNALSWhy Is Regeneron Pharmaceuticals (REGN) Stock Down -6% Today?
Key Takeaways
- Shares of Regeneron Pharmaceuticals (REGN) are down approximately 6% on Wednesday, trading near $688 after closing at $731.77 on April 28, in an earnings-driven selloff despite a headline beat on both EPS and revenue
- Primary catalyst: A sharp "beat and sell" market reaction driven by the continued deterioration of the core EYLEA franchise — total U.S. EYLEA HD and EYLEA net sales declined 10% year-over-year to $941 million, more than offsetting record Dupixent growth
- Secondary catalyst: Regeneron's Trump administration Most-Favored Nation (MFN) drug pricing deal — signed just six days before earnings — commits the company to significant long-term drug price reductions across Medicaid and future therapies, raising concerns about structural margin compression
- GAAP gross margin contracted due to temporary manufacturing issues disclosed in the Q1 report, adding further pressure on profitability optics
- Eylea 2mg biosimilar competition is expected to accelerate in H2 2026 as multiple additional products enter the market, a risk the market is pre-emptively pricing in
- Traders are watching the anticipated fianlimab + Libtayo melanoma Phase 3 data readout and management's H2 2026 commentary around EYLEA HD conversion pacing
Opening Summary
Regeneron Pharmaceuticals, Inc. (REGN) is a Tarrytown, New York–based biotechnology company that develops and commercializes transformative medicines, with its flagship products including the immunology blockbuster Dupixent (co-developed with Sanofi), the ophthalmology franchise EYLEA and EYLEA HD, and oncology therapy Libtayo. Shares fell approximately 6% on Wednesday, declining from a prior close of $731.77 to trade near $688, despite a Q1 2026 print that beat consensus on both adjusted EPS and revenue. The paradoxical selloff reflects a combination of EYLEA franchise deterioration, investor concern over the company's newly signed MFN drug pricing agreement with the Trump White House, and a GAAP gross margin decline tied to temporary manufacturing disruptions — all of which outweighed the headline beat in the market's eyes.
Q1 2026 Earnings: Headline Beat, Franchise Headache
Regeneron delivered Q1 2026 non-GAAP EPS of $9.47, beating the consensus estimate of $9.07 by $0.40 — a 6.56% positive surprise. Revenue reached $3.61 billion, up 19% year-over-year and ahead of the $3.55 billion consensus by approximately $53 million. Dupixent global net sales recorded by Sanofi surged 33% to $4.9 billion, sustaining its position as one of the fastest-growing blockbusters in the industry. EYLEA HD U.S. net sales grew 52% year-over-year to $468 million, validating the higher-dose reformulation strategy. However, when combining EYLEA HD with the legacy EYLEA 2mg franchise, total U.S. EYLEA net sales declined 10% year-over-year to $941 million — the most closely watched number in the quarter and the one that spooked investors most acutely. A temporary manufacturing issue also suppressed GAAP gross margins below year-ago levels, adding further optics pressure despite non-GAAP profitability.
MFN Drug Pricing Deal: Long-Term Revenue Overhang
Six days before reporting earnings, Regeneron became the 17th and final major pharmaceutical company to sign the Trump administration's Most-Favored Nation pricing agreement. Under the terms of the deal, Regeneron committed to align its current and future Medicaid drug prices with the lowest prices paid in comparable developed nations, offer its cholesterol drug Praluent on TrumpRx.gov at $225 — a 58% discount from its prior $537 price — and invest $27 billion in U.S. research, development, and manufacturing through 2029. In exchange, REGN secured a three-year exemption from pharmaceutical tariffs and immunity from future pricing mandates. While the stock initially rose 2.6% on the deal announcement, investors are now reassessing the long-term margin implications — particularly as future drug launches must be priced at most-favored-nation levels from day one, a structural constraint that affects Regeneron's highest-margin commercialization window.
Accelerating Biosimilar Pressure on EYLEA
The EYLEA franchise — historically the backbone of Regeneron's revenue — faces a worsening competitive landscape that Q1 2026 results made more concrete. EYLEA 2mg U.S. sales have been in structural decline as biosimilar competition, compounded bevacizumab substitution, and patient migration to EYLEA HD have eroded volumes. While EYLEA HD's 52% growth is encouraging, the pace of conversion has not been sufficient to fully offset the legacy product's declining base — a gap the market expects to widen materially in H2 2026 as multiple additional EYLEA biosimilar entrants are scheduled to launch. TD Cowen and other analysts have previously flagged the H2 biosimilar acceleration as the key risk that consensus estimates may only be partially pricing in, making the Q1 franchise total of $941 million a sobering preview of the trajectory ahead.
Market Context and Trading Activity
The REGN selloff was company-specific and earnings-driven, with the broader biotech and healthcare sector not registering comparable losses on Wednesday. Volume surged well above the average daily level as institutional sellers responded to the EYLEA revenue figure immediately following the pre-market earnings release. The stock entered the day already testing the lower bound of its 52-week range of $476.49–$821.11, having underperformed the Nasdaq materially since its October 2025 highs. REGN had already broken below its 50-day moving average in early April 2026 and its 10-day average had crossed bearishly below the 50-day on March 13, establishing a downtrend that Wednesday's session reinforced.
Trending AI Robots
For traders navigating volatile, earnings-driven sessions like today's REGN move, Tickeron's Trending AI Robots page provides a curated ranking of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI bots covering thousands of tickers across biotechnology, healthcare, technology, and all major sectors — but only those demonstrating the strongest real-time performance metrics are featured in this dynamic, live-updated section. Bots vary by strategy, holding timeframe, risk tolerance, and traded symbols, spanning short-term momentum plays to multi-session swing strategies. Whether you are managing risk around post-earnings dislocations or seeking systematic approaches to capitalize on sharp directional moves, the Trending AI Robots page is a practical starting point for data-driven traders.
What Comes Next for REGN
The most closely anticipated catalyst for REGN) is the Phase 3 data readout for fianlimab plus Libtayo in first-line metastatic melanoma, expected in H1 2026, which TD Cowen and others view as a potential transformational moment for Regeneron's oncology franchise. A strong fianlimab result could establish Libtayo as a credible blockbuster competitor in a large oncology market, providing a meaningful revenue diversification catalyst beyond the Dupixent and EYLEA narratives. H2 2026 EYLEA 2mg biosimilar entry volume will be the primary ongoing financial variable — the rate of EYLEA HD conversion against accelerating legacy erosion will determine whether the retinal franchise stabilizes or declines faster than consensus. The MFN pricing framework, while temporarily resolved for REGN on tariffs, remains politically fluid — Democratic lawmakers have publicly requested detailed terms of all MFN agreements from drugmakers, and any legislative or regulatory development in this area could reprice the sector broadly. Analysts will also monitor whether the Q1 GAAP manufacturing disruption proves genuinely temporary, as any recurrence would further compress reported margins and challenge the non-GAAP narrative the company has maintained.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
REGN in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 56 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 31 of 50 cases over the following month. The odds of a continued upward trend are 62%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +17.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 186 of 268 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.121) is normal, around the industry mean (3.104). P/E Ratio (22.958) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (129.907) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement